Investors & media
Financial data
Find the latest press releases, financial information, and performance updates.
Transforming rare disease care
We are a global specialty biopharmaceutical company expanding possibilities for people with rare diseases. With 50 years of experience in applying our scientific expertise and unique technologies to research, we continue to develop next-generation treatments and expand our global footprint to transform the lives of patients worldwide.
Newsroom
2026.01.28
FY2025-Q3 financial report (Oct. 1-Dec. 31, 2025)
2026.01.28
Revision of consolidated financial forecasts for fiscal year ended March 31, 2026
2026.01.28
Recognition of subsidy income as extraordinary income
2026.01.28
FY2025 third quarter results briefing session material
2026.01.28
Briefing session movie on the agreement with Italfarmaco
Performance data and annual reports
JCR Pharmaceuticals (4552.T)
Tokyo Currency in JPY
645.00
+15.00
(+2.38%)
Last updated 01/30/2026 at TSE market close
Quarterly results
Annual reports
Driven by science and compassion, we tackle some of the most complex challenges in rare disease. Every solution we develop is grounded in insight into the genetic and biological foundations of the conditions we aim to treat.
Contact us
Investors & media